Abstract
Two-stage enrichment designs can be used to target the benefiting population in clinical trials based on patients’ biomarkers. In the case of continuous biomarkers, we show that using a bivariate model that treats biomarkers as random variables more accurately identifies a treatment-benefiting enriched population than assuming biomarkers are fixed. Additionally, we show that under the bivariate model, the maximum likelihood estimators (MLEs) follow a randomly scaled mixture of normal distributions. Using random normings, we obtain asymptotically standard normal MLEs and construct hypothesis tests. Finally, in a simulation study, we demonstrate that our proposed design is more powerful than a single stage design when outcomes and biomarkers are correlated; the model-based estimators have smaller bias and mean square error (MSE) than weighted average estimators.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
